2022 World Conference on Lung Cancer (ePosters)-EP07.01-021. Clinical and Biochemical Profiling of Pleural Mesothelioma Patients Treated With Immunotherapy

Pdf Summary

A study was conducted to assess the clinical value of inflammation-based biomarkers in patients with pleural mesothelioma who were treated with immunotherapy. Pleural mesothelioma is a rare and highly deadly disease, and there is a need to predict treatment response and overall prognosis. Currently, platinum-based chemotherapy is the only approved treatment, but immunotherapy has shown promise in recent studies.<br /><br />The study enrolled 30 patients, of which 22 received immunotherapy (combination of ipilimumab plus nivolumab or nivolumab alone) and 8 received chemotherapy followed by immunotherapy. The median follow-up period was 12.5 months, with a median overall survival of 25.4 months and a median progression-free survival of 8.4 months.<br /><br />The researchers found that disease control rate and overall response rate were associated with performance status (PS), CRP-to-albumin ratio (CAR), Glasgow Prognostic Score (GPS), and neutrophil-to-lymphocyte ratio (NLR). Patients with PS 0-1, CAR 7.5, GPS 0, and NLR 5 had better disease control and response rates. In terms of survival, better progression-free survival was associated with PS 0-1 and NLR 5, while overall survival was better in patients with PS 0-1, CAR 7.5, NLR 5, and GPS 0.<br /><br />The study suggests that there is an association between inflammatory biomarkers and prognosis in patients with pleural mesothelioma treated with immunotherapy or chemotherapy followed by immunotherapy. These biomarkers, such as PS, CAR, NLR, and GPS, are easily measurable and may be useful in predicting the efficacy of immunotherapy in these patients.<br /><br />Further validation of these findings is needed through prospective studies. If confirmed, these biomarkers could provide valuable insights for personalized treatment approaches and predicting treatment outcomes in pleural mesothelioma patients.

Asset Subtitle

Sara Manglaviti

Meta Tag

Speaker Sara Manglaviti

Topic Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical

Keywords

inflammation-based biomarkers

pleural mesothelioma

immunotherapy

platinum-based chemotherapy

treatment response

disease control rate

progression-free survival

overall survival

prospective studies

personalized treatment approaches